Hayward, Calif., Nov. 18, 2013 -- Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics market, today announced that it has closed a structured debt financing with Capital Royalty Partners L.P. The transaction provides Solta with $40 million for working capital.
"With the completion of this secured debt agreement, we have the necessary working capital to aggressively pursue our plans for 2014 to regain momentum and revenue growth," said Mark Sieczkarek, Interim CEO of Solta Medical. "New sales leadership in North America and Europe, combined with significant changes in our sales and marketing approach, are already generating…Read More »
Albuquerque, New Mexico – November 4, 2013 – Exagen Diagnostics, Inc. and Capital Royalty Partners II, L.P. announced that they have closed a senior secured loan for up to $25 million of capital. Exagen’s lead test, Avise SLE+ Connective Tissue, rules in-or-out Systemic Lupus Erythematosus (SLE) and assists with differential diagnosis of other common Connective Tissue Disease (CTD). Exagen intends to use proceeds to grow its US sales force to 25-30 representatives to fuel continued strong revenue growth in SLE+ and pipeline of rheumatology tests.
“Capital Royalty has shown to be the right partner for us and we are extremely excited…Read More »
Financing Proceeds to Accelerate Growth and Market Expansion in Leading Digital PCR and Next-Gen Sequencing Products
Billerica, Mass – September 23, 2013 – RainDance Technologies, Inc., an innovative genomics tools company enabling ultra-sensitive detection of cancer and inherited diseases, today announced it has closed a structured debt financing with Capital Royalty Partners L.P. The transaction provides RainDance with up to $35 million to support commercial expansion of the company’s leading Digital PCR and Next-Generation Targeted DNA Sequencing products. This financing builds on RainDance’s $20 million Series E equity financing announced in April 2013. Armentum Partners acted as financial advisors…Read More »
Valeritas Expanding V-Go US Commercial Operations
Bridgewater, N.J., June 4, 2013 (PR NEWSWIRE) – Valeritas, makers of the V-Go® insulin delivery device, today announced that they have closed a structured debt financing with Capital Royalty L.P. which provides Valeritas with up to $100 million to further support the commercialization of the V-Go.
"We are pleased to have Capital Royalty as a financial partner," said Kristine Peterson, Valeritas Chief Executive Officer. "This financing gives us further flexibility to expand our US commercial efforts for V-Go and bring this innovative treatment approach to many more patients with Type 2 diabetes."
… Read More »
CAMBRIDGE, Massachusetts, May 8, 2013 - Good Start Genetics®, Inc., an innovative molecular diagnostics company that has developed the new gold standard in carrier screening, today announced that it has closed a non-dilutive loan facility for up to $28 million of capital from Capital Royalty L.P. Good Start Genetics will use the proceeds to support its long-term corporate growth initiatives for the company’s next-generation sequencing (NGS) based carrier screening platform.
“Our investment in Good Start Genetics is consistent with our focus on providing flexible financing solutions for innovative companies with commercial technologies,” said Charles Tate, Chairman and Founder of Capital Royalty…Read More »
Total Investable Capital Expected to Exceed $1 Billion Including Debt Financing
HOUSTON, TX May 2, 2013 -- Capital Royalty L.P., a pioneer in healthcare investing, today announced the final closing of Capital Royalty Partners II L.P. with $805 million in equity commitments.
Capital Royalty Partners II, the Firm’s second private equity fund, was oversubscribed and exceeded its initial fund raising target. Total investable capital is expected to exceed $1 billion including debt financing facilities available to the Fund. The Fund’s global investor base consists of world-class limited partners, including pension funds, endowments, institutional investors, funds of funds, family…Read More »
Santa Rosa, CA, February 5, 2013 – TriVascular, Inc. (“TriVascular” or the “Company”) and Capital Royalty Partners II, L.P. (“Capital Royalty”) announced that they have closed a term loan facility. The financing represents Capital Royalty Fund II’s largest commitment to date.
TriVascular is a privately-owned medical device company focused on developing novel endovascular aortic repair (EVAR) stent graft systems for the treatment of aortic aneurysms. The Company received FDA approval of the Ovation and Ovation Prime Abdominal Stent Graft Systems during the fourth quarter of 2012 for the treatment of abdominal aortic aneurysms. Ovation and Ovation Prime combine the smallest…Read More »
San Diego, January 23, 2013 –Tandem Diabetes Care®, Inc. (“Tandem” or the “Company”) and Capital Royalty Partners II, L.P. (“Capital Royalty”) today announced that they have closed a term loan facility that provided Tandem with $30 million, and up to an additional $15 million based on certain revenue milestones.
Tandem is a privately-owned medical device company that focuses on advancing the management of diabetes through novel technologies. The Company announced FDA clearance for its lead product, the t:slim® Insulin Pump, in November 2011 and began shipping to customers on August 31, 2012. The t:slim Pump has a vivid color touch…Read More »